CAR-T cells have quickly shown great potential in manipulating the immune system and regulatory authorities are starting to approve CAR-T cell therapies to treat diseases such as large B-cell lymphoma. Additionally, T-cell receptor (TCR)-engineered T cells are both novel options for adoptive cell therapy used for the treatment of several advanced forms of cancer. Before CAR and TCR cell are applied to clinical immunotherapy, in vitro assays and pre-clinical in vivo assays are indispensable and significant steps. BioCytoceuticals provides systematic service for CAR cells in vitro/in vivo assays during CAR-T, CRA-NK, and TCR cells development.
CAR-T cells have quickly shown great potential in manipulating the immune system and regulatory authorities are starting to approve CAR-T cell therapies to treat diseases such as large B-cell lymphoma. Moreover, unlike CAR-T cells, CAR-NK cells can still exert their “natural” anti-leukemia effect when the tumor antigen targeted by CAR is downregulated. However, understanding the variability of sample preparation and establishing quality measures that are predictive of potency, safety and consistency for manufacturing purposes are still challenging issues.
T-cell receptor (TCR)-engineered T cells are novel options for adoptive cell therapy used for the treatment of several advanced forms of cancer. BioCytoceuticals specializes in performing comprehensive quality assessment on TCR-engineered cells both in vitro and in vivo, and we are more than happy to design service plan specifically catered for your goals.
BioCytoceuticals leads the industry in cellular therapy with commitment to provide the most appropriate solutions to address the needs of our clients. Our expert team of scientists applies comprehensive methods and most detail-oriented scrutiny to ensure only top-tier outcome is submitted.
If you have any special enquiries regarding our In Vitro/In Vivo Assays Development, please do not hesitate to contact us. Our highly professional technical supporting staffs will make sure your requests are faithfully received. We are looking forward to earn your business.
Inquiry
